UMPIRE - Trial of an implantable device for continuous monitoring of epileptic seizure activity.

Focal and Generalised Epilepsy

Epileptic seizures result from abnormal electrical activity in the brain, which can be monitored by electroencephalography (EEG).  EEG monitoring may improve the detection, treatment and potentially prediction of seizures, but the equipment is cumbersome and the test is time consuming.  As a result, long term seizure monitoring is often impractical and seizures are often missed during routine evaluations.  The UMPIRE study evaluates the safety of Minder, an experimental device, implanted under the scalp for continuous monitoring of seizure activity.  Brain activity data recorded in the study will be analysed to evaluate its utility for detecting epileptic activity and seizures.

Trial Status
Trial Phase
Medical Device Pilot Study
Trial contact details
Contact Person
Delphine Lévy-Bencheton
What you need to know

Who can take part?

  • People aged 18 to 75, diagnosed with focal or generalised epilepsy
  • People with a minimum of 2 seizures per month (focal or generalized epilepsy)
  • Female participants of childbearing potential must avoid pregnancy during the study
  • Not open to participants with another implanted neurostimulation device, including vagus nerve stimulation, deep brain stimulation or cochlear implants

What is involved for you?

Participants will have the Minder device surgically implanted behind one ear, with an electrode implanted under the scalp along the back of the head. Participants are given a wearable device to transmit EEG data to a mobile phone. They will also have the following procedures and tests:

  • Blood tests
  • Electrocardiogram
  • Physical exam and vital signs
  • CT Scan
  • Two 7-day video EEG monitoring sessions during the 6 month study
  • Keep a seizure diary

Trial dates

This trial is accepting participants until July 2023.

All research clinical trials news

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.



Clinical Trials Coordinator Yvonne Gautam is working towards creating better treatments for patients with diabetes

Displaying results 1-3 (of 16)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|